<p>Effects of High-Dose Rosuvastatin on Ventricular Remodelling and Cardiac Function in ST-Segment Elevation Myocardial Infarction</p>

Abstract

To investigate the effects of high-dose rosuvastatin on ventricular remodelling and cardiac function in ST-segment elevation myocardial infarction (STEMI). Materials and Methods: From January 2017 to March 2019, the clinical data of 93 patients with STEMI were collected and analysed, with 46 cases in the conventional-dose group (rosuvastatin, 10 mg/d) and 47 cases in the high-dose group (rosuvastatin, 20 mg/d). Blood lipid (TC, TG, LDL-C and HDL-C), serum inflammatory markers (hs-CRP, IL-6, TNF-α and ICAM-1), ventricular remodelling markers (NT-pro BNP, MMP-9, TIMP-4 and Gal-3) and indicators of cardiac function (LVESD, LVESD, LVESV, LVEDV, IVST and LVEF) were collected from all patients at the time of admission and 8 weeks after rosuvastatin treatment. Results: After treatment with rosuvastatin for 8 weeks, compared with those in conventional-dose group, the levels of TC, TG, LDL-C, hs-CRP, IL-6, TNF-α, ICAM-1, NT-pro BNP, MMP-9 and Gal-3 in the high-dose group decreased significantly (P<0.05), while the increase of HDL-C and TIMP-4 levels was more obvious (P<0.05) than that in the conventional-dose group. Moreover, LVEF was significantly higher (P<0.05) and LVESD, LVESD, LVESV, LVEDV and IVST were significantly lower (P< 0.05) after treatment than before treatment in both groups. The improvement of cardiac ultrasound results in the high-dose group was more significant than that in the conventional-dose group (P< 0.05). Conclusion: This study suggests that high-dose rosuvastatin was better than conventionaldose rosuvastatin for improving blood lipid metabolism, reducing the inflammatory response, and preventing and treating ventricular remodelling and myocardial fibrosis, indicating that high-dose rosuvastatin had stronger therapeutic effect on STEMI than conventional-dose rosuvastatin.

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol

“…This finding is consistent with Luo et al . (2020) [ 30 ]. High doses of rosuvastatin (20 mg/day; eight weeks) can significantly decrease serum levels of ICAM-1, IL-6 and TNFα in patients with ST-segment elevation myocardial infarction (STEMI).…”

Inflammatory markers in patients who presented with acute coronary syndrome and history of COVID-19 infection: a cross-sectional study

“…While STEMI had a significantly increased number and mean proportion of ACS patients who had COVID-19 where it was 32 patients and the mean proportion was 76.2%, dyslipidemia had a significantly increased number and mean proportion of ACS patients who had not had COVID-19; 26 patients and a mean proportion of 54.2%. Unstable angina was observed only in the group of ACS patients who had not COVID-19 where their number was 17 and the mean proportion was 35.4% (see Table 1).…”

Obstructive Sleep Apnea and Cardiovascular Risk: The Role of Dyslipidemia, Inflammation, and Obesity

“…A low value of HDL cholesterol is associated with left ventricle remodeling and diastolic dysfunction, especially in patients with hypertension, which is significant as the majority of the patients with OSA have it ( Horio et al, 2003 ). Regarding the potential benefits of lipid-lowering therapy, it is shown that high-dose statin therapy can improve blood lipid metabolism, reduce the inflammatory response, and prevent and treat ventricular remodeling and myocardial fibrosis ( Luo et al, 2020 ). These positive effects can significantly reduce cardiovascular risk and improve further prognosis.…”